PMID: 21499296
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
Abstract
Despite the initial effectiveness of the tyrosine kinase inhibitor lapatinib against HER2 gene-amplified breast cancers, most patients eventually relapse after treatment, implying that tumors acquire mechanisms of drug resistance. To discover these mechanisms, we generated six lapatinib-resistant
| PTM Type | Substrate | Site | PTM Enzyme | Source |
|---|---|---|---|---|
| Phosphorylation |
iPTM:P04626
(ERBB2)
  PRO
|
Y1248 | RLIMS-P | |
| Phosphorylation |
iPTM:P12931
(SRC)
PRO
|
Y216 | RLIMS-P |
